Long-term improvement by ozone treatment in chronic pain secondary to chemotherapy-induced peripheral neuropathy: A preliminary report.

Autor:	Clavo B; Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.; Chronic Pain Unit, Dr. Negrín University Hospital, Las Palmas de Gran Canaria, Spain.; Radiation Oncology Department, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain.; Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria, Spain.; Molecular and Translational Pharmacology Group, Universitary Institute for Research in Biomedicine and Health (iUIBS), University of Las Palmas de Gran Canaria, Las Palmas de Gran Canaria, Spain.; Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias de la Universidad de La Laguna, Tenerife, Spain.; Research Network on Health Services in Chronic Diseases (REDISSEC), Instituto de Salud Carlos III, Madrid, Spain.; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain.; Spanish Group of Clinical Research in Radiation Oncology (GICOR), Madrid, Spain., Rodríguez-Abreu D; Medical Oncology Department, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Las Palmas de Gran Canaria, Spain., Galván S; Medical Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain., Federico M; Radiation Oncology Department, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain., Martínez-Sánchez G; Scientific Advisor, Freelance, Ancona, Italy., Ramallo-Fariña Y; Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria, Spain.; Research Network on Health Services in Chronic Diseases (REDISSEC), Instituto de Salud Carlos III, Madrid, Spain.; Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Tenerife, Spain., Antonelli C; Medical Oncology Department, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain., Benítez G; Medical Oncology Department, Complejo Hospitalario Universitario Insular Materno-Infantil de Gran Canaria, Las Palmas de Gran Canaria, Spain., Rey-Baltar D; Radiation Oncology Department, Hospital Universitario Dr. Negrín, Las Palmas de Gran Canaria, Spain., Jorge IJ; Chronic Pain Unit, Dr. Negrín University Hospital, Las Palmas de Gran Canaria, Spain., Rodríguez-Esparragón F; Research Unit, Hospital Universitario de Gran Canaria Dr. Negrín, Las Palmas de Gran Canaria, Spain.; Fundación Canaria Instituto de Investigación Sanitaria de Canarias (FIISC), Las Palmas de Gran Canaria, Spain.; Instituto Universitario de Enfermedades Tropicales y Salud Pública de Canarias de la Universidad de La Laguna, Tenerife, Spain.; CIBER de Enfermedades Infecciosas (CIBERINFEC), Instituto de Salud Carlos III, Madrid, Spain., Serrano-Aguilar P; Research Network on Health Services in Chronic Diseases (REDISSEC), Instituto de Salud Carlos III, Madrid, Spain.; Network for Research on Chronicity, Primary Care, and Health Promotion (RICAPPS), Tenerife, Spain.; Servicio de Evaluación y Planificación del Servicio Canario de Salud (SESCS), Santa Cruz de Tenerife, Spain.; Red de Agencias de Evaluación de Tecnologías Sanitarias y Prestaciones del Sistema Nacional de Salud (RedETS), Madrid, Spain.
Jazyk:	angličtina
Zdroj:	Frontiers in physiology [Front Physiol] 2022 Aug 30; Vol. 13, pp. 935269. Date of Electronic Publication: 2022 Aug 30 (Print Publication: 2022).
DOI:	10.3389/fphys.2022.935269
Abstrakt:	Background: Pain secondary to chemotherapy-induced peripheral neuropathy (CIPN) can limit the administration of chemotherapy, cancer-treatment outcomes, and the quality of life of patients. Oxidative stress and inflammation are some of the key mechanisms involved in CIPN. Successful treatments for CIPN are limited. This report shows our preliminary experience using ozone treatment as a modulator of oxidative stress in chronic pain secondary to CIPN. Methods: Ozone treatment, by rectal insufflation, was administered in seven patients suffering from pain secondary to grade II or III CIPN. Pain was assessed by the visual analog scale (VAS). Results: All patients, except one, showed clinically relevant pain improvement. Median pain score according to the VAS was 7 (range: 5-8) before ozone treatment, 4 (range: 2-6) at the end of ozone treatment ( p = 0.004), 5.5 (range: 1.8-6.3) 3 months after the end of ozone treatment ( p = 0.008), and 6 (range: 2.6-6.6) 6 months after the end of ozone treatment ( p = 0.008). The toxicity grade, according to the Common Terminology Criteria for Adverse Events (CTCAE v.5.0), improved in half of the patients. Conclusion: This report shows that most patients obtained clinically relevant and long-lasting improvement in chronic pain secondary to CIPN after treatment with ozone. These observed effects merit further research and support our ongoing randomized clinical trial (NCT04299893). Competing Interests: The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest. (Copyright © 2022 Clavo, Rodríguez-Abreu, Galván, Federico, Martínez-Sánchez, Ramallo-Fariña, Antonelli, Benítez, Rey-Baltar, Jorge, Rodríguez-Esparragón and Serrano-Aguilar.)
Databáze:	MEDLINE
Externí odkaz:	Zobrazit plný text záznamu